LGND:NASDAQ
Ligand Pharmaceuticals Inc
307,22 $
arrow_downward
−1,01%(−3,14) 1D
30. sep., 10:18:05 GMT -4 · USD
search
Vsi simboli
1D
5D
1M
6M
TLDD
1L
5L
MAKS
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za LGND …
Odpri
310,52 $
Visoka
310,52 $
Nizka
306,98 $
Tržna kapitalizacija
6,12 mrd.
Povprečni promet
222,66 tis.
Promet
13,26 tis.
Razmerje med ceno delnice in čistim dobičkom
32,68
52-tedenski najvišji tečaj
326,63 $
52-tedenski najnižji tečaj
175,89 $
Čisti dobiček na delnico
9,40 $
Beta
1,03
Št. izdanih delnic
19,94 mio.
Št. zaposlenih
47
Odpri
310,52 $
Visoka
310,52 $
Nizka
306,98 $
Tržna kapitalizacija
6,12 mrd.
Povprečni promet
222,66 tis.
Promet
13,26 tis.
Razmerje med ceno delnice in čistim dobičkom
32,68
52-tedenski najvišji tečaj
326,63 $
52-tedenski najnižji tečaj
175,89 $
Čisti dobiček na delnico
9,40 $
Beta
1,03
Št. izdanih delnic
19,94 mio.
Št. zaposlenih
47
Novice
Iz spletnih virov in novičarskih partnerjev
Investing.com Canada
·
pred 1 dnevom
Form 4 Ligand Pharmaceuticals Incorporated For: 28 September By Investing.com
Profil
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments.
Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
Vizitka: Ligand Pharmaceuticals Inc
Generalni direktor-
Št. zaposlenih47
Ustanovljenosep. 1987
SedežJupiter, Florida, Združene države Amerike
Sektor-
Spletno mestoligand.com